For example, splicing factor SF3B1 has been shown to generate immunogenic neoantigens in uveal melanoma.[11] Accordingly, animal researches have revealed that modulation of RNA splicing by chemical compounds can generate neoantigens, which in turn prime CD8+ T cells and enhance the anti‐tumor immune response.[12] During cancer progression, alternative splicing is found to be disturbed and accumulation of neoantigens are expected to elicit anti‐tumor immunity. Here, CD8A is linked to cancer.